1 of 3
FEATURED COMPANIES
- Biogen Idec (US)
- Cephalon, Inc. (US)
- Eisai, Ltd. (Japan)
- EpiCept Corp. (US)
- Genentech, Inc. (US)
- Genitope Corp. (US)
- MORE
This report analyzes the worldwide markets for Lymphoma Therapeutics in US$ Million.
The report provides separate comprehensive analytics for US, Europe, and Rest of World.
Annual estimates and forecasts are provided for each region for the period 2006 through 2015.
The report profiles 93 companies including many key and niche players such as Allos Therapeutics, Inc., Astellas Pharma US, Inc., Biogen Idec, Biolex Therapeutics, Inc., Biovest International, Inc., Cell Therapeutics, Inc, Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Cyclacel Pharmaceuticals, Inc., Eisai, Ltd., EpiCept Corp., F. Hoffmann-la Roche Ltd., Genentech, Inc., Genmab, Genitope Corp., Genzyme Corporation, GlaxoSmithKline, Plc, Hana Biosciences, Inc., ImmunoGen, Inc., InNexus Biotechnology, Inc., and Millennium Pharmaceuticals, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying.
The report provides separate comprehensive analytics for US, Europe, and Rest of World.
Annual estimates and forecasts are provided for each region for the period 2006 through 2015.
The report profiles 93 companies including many key and niche players such as Allos Therapeutics, Inc., Astellas Pharma US, Inc., Biogen Idec, Biolex Therapeutics, Inc., Biovest International, Inc., Cell Therapeutics, Inc, Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Cyclacel Pharmaceuticals, Inc., Eisai, Ltd., EpiCept Corp., F. Hoffmann-la Roche Ltd., Genentech, Inc., Genmab, Genitope Corp., Genzyme Corporation, GlaxoSmithKline, Plc, Hana Biosciences, Inc., ImmunoGen, Inc., InNexus Biotechnology, Inc., and Millennium Pharmaceuticals, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying.
Note: Product cover images may vary from those shown
2 of 3
FEATURED COMPANIES
- Biogen Idec (US)
- Cephalon, Inc. (US)
- Eisai, Ltd. (Japan)
- EpiCept Corp. (US)
- Genentech, Inc. (US)
- Genitope Corp. (US)
- MORE
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Types of Lymphomas I-3
Hodgkin’s lymphoma I-3
Non-Hodgkin’s lymphoma I-3
II. Executive Summary
1. GLOBAL OUTLOOK II-1
Global Lymphoma Therapeutics Market to Surge II-1
Europe Leads the Global Lymphoma Therapeutics Market II-1
Lymphoma Incidence and Mortality Rates On the Rise II-1
Incidence of Hodgkins Lymphoma - High in West Asia II-2
Table 1: Age-Standardized Incidence Rates for Hodgkin’s
Lymphoma in Select Countries Worldwide (2002) (includes
corresponding Graph/Chart) II-2
Table 2: Age-Standardized Mortality Rates for Hodgkin’s
Lymphoma in Select Countries Worldwide (2002) (includes
corresponding Graph/Chart) II-3
Rituxan’s Dominance - A Major Hurdle to Other Emerging Drugs II-3
Huge Unmet Needs to Drive Product Innovation II-4
Radioimmunotherapy Drug Penetration Continues to Remain Lower II-4
Table 3: Monthly Cost of Select Non-Hodgkin’s Lymphoma
Treatments (2009) II-4
Sales of Zevalin to Gain Momentum II-5
Combination Drugs - A Potential Winning Option for Manufacturers II-5
Existing Drugs for Lymphoma II-6
Select Approved Drugs In Lymphoma Treatment II-6
Rituxan - the Undisputed Leader in NHL Drugs II-6
Key Indications for Rituxan in the US II-7
Zevalin (Biogen Idec) II-7
Overview II-7
Administration II-8
Efficacy II-8
Bexxar (GlaxoSmithKline) II-9
Ribomustin®/Treanda® II-9
Pipeline Drugs for Lymphoma II-9
Select Pipeline Drugs In Lymphoma Treatment II-9
Select Vaccines In Pipeline for Lymphoma Treatment II-11
Pixantrone (Cell Therapeutics) II-11
Affinitor (Novartis) II-11
SGN-35 (Seattle Genetics) II-11
SAR3419 (ImmunoGen, Inc.) II-12
Overview of Treatment Options for NHL II-12
Chemotherapy II-12
Radiotherapy II-13
Antibody Therapy II-13
Stem Cell Transplants II-13
2. PRODUCT OVERVIEW II-14
Lymphomas II-14
Types of Lymphomas II-14
Hodgkin’s lymphoma II-14
Non-Hodgkin’s lymphoma II-14
Classification - Based on Type of Cells Involved II-14
Hodgkin’s Lymphomas II-15
Natural Killer (NK) and Mature T cell Neoplasms II-15
Mature B cell Neoplasms II-15
Classification - Based on Disease Progression II-16
Indolent Lymphomas II-16
Aggressive Lymphomas II-16
Background II-17
Signs and Symptoms II-17
Etiology and Risk Factors II-17
Immunological functions II-18
Infections II-18
Lifestyle Factors II-18
Diagnosis of Lymphoma II-18
Prognosis II-18
Treatment of Lymphoma II-19
3. DRUG APPROVALS II-20
Gloucester Obtains FDA Clearance for Istodax® in Treating CTCL II-20
Allos Obtains FDA Approval for FOLOTYN™ II-20
Spectrum Receives FDA Approval for Zevalin® Expanded Label II-20
Genzyme Receives European Commission Approval for Mozobil® II-21
Cephalon Obtains FDA Approval for TREANDA for Treating
Indolent NHL II-21
GSK Receives European Approval for Atriance® II-22
4. RECENT INDUSTRY ACTIVITY II-23
Celgene to Acquire Gloucester Pharmaceuticals II-23
Scientists at Cornell Discover New Molecular Mechanism for
Treating NHL II-23
CTI Seeks Orphan Drug Designation for Pixantrone in Europe II-24
FDAs ODAC Recommends Romidepsin’s Approval II-24
Seattle Genetics Completes Enrollment for Brentuximab Vedotin II-24
InNexus Biotechnology to Initiate Business Development for DXL625 II-25
Allos Therapeutics Introduces focusonptcl.com II-25
InNexus Inks Letter of Intent with Genhelix II-25
Pfizer Acquires Wyeth II-25
LLS and FORMA Join Hands to Accelerate Development of New
Therapies II-26
Biovest and idis Ink Partnership Deal for Distribution of
BiovaxID® II-26
SymBio Pharmaceuticals Signs a License Agreement with Eisai II-27
Seattle Genetics Receives Fast Track Designation from FDA for
SGN-35 II-27
Spectrum Acquires ZEVALIN® from RIT Oncology II-27
EpiCept Announces Crinobulin as Generic Name for EPC2407 II-27
CTI Enters Into a Joint Venture with Spectrum Pharmaceuticals II-28
Allos Receives Orphan Drug Designation for Pralatrexate from FDA II-28
Takeda Acquires Millennium Pharmaceuticals II-28
5. FOCUS ON SELECT GLOBAL PLAYERS II-29
Allos Therapeutics, Inc. (US) II-29
Astellas Pharma US, Inc. (US) II-29
Biogen Idec (US) II-29
Biolex Therapeutics, Inc. (US) II-30
Biovest International, Inc. (US) II-30
Cell Therapeutics, Inc. (US) II-31
Cephalon, Inc. (US) II-31
Chugai Pharmaceutical Co., Ltd. (Japan) II-31
Cyclacel Pharmaceuticals, Inc. (US) II-32
Eisai, Ltd. (Japan) II-32
EpiCept Corp. (US) II-33
F. Hoffmann-la Roche Ltd. (Switzerland) II-33
Genentech, Inc. (US) II-33
Genmab (Denmark) II-34
Genitope Corp. (US) II-34
Genzyme Corporation (US) II-35
GlaxoSmithKline, Plc. (UK) II-35
Hana Biosciences, Inc. (US) II-35
ImmunoGen, Inc. (US) II-36
InNexus Biotechnology, Inc. (Canada) II-36
Millennium Pharmaceuticals, Inc. (US) II-36
6. GLOBAL MARKET PERSPECTIVE II-38
Table 4: World Recent Past, Current & Future Analysis for
Lymphoma Drugs Market by Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-38
Table 5: World 10-year Perspective for Lymphoma Drugs Market
by Geographic Region - Percentage Breakdown of Value Sales for
US, Europe and Rest of World Markets for Years 2006, 2009 &
2015 (includes corresponding Graph/Chart) II-39
III. MARKET
1. UNITED STATES III-1
A.Market Analysis III-1
Rising Incidence of Lymphomas to Fuel Market Growth III-1
Mortality Rate Slips III-1
Lymphomas - The Third Leading Cause of Cancer in Children III-1
Table 6: Percentage Breakdown of Cancer Incidence in US
Children by Type (2006) (includes corresponding
Graph/Chart) III-2
White Children - Most Susceptible to Lymphomas III-2
Table 7: Incidence of Lymphoma in US Children in 2006
(includes corresponding Graph/Chart) III-2
Lymphoma Fact Sheet III-3
Incidence Rate Rises in Afro-Americans III-3
Table 8: US Lymphoma Incidence Rates in Men of All Ages by
Race: 2002-2006 (includes corresponding Graph/Chart) III-3
Table 9: US Lymphoma Incidence Rates in Women of All Ages
by Race: 2002-2006 (includes corresponding Graph/Chart) III-4
Table 10: US Lymphoma Mortality Rates in Men of All Ages by
Race: 2002-2006 (includes corresponding Graph/Chart) III-4
Table 11: US Lymphoma Mortality Rates in Women of All Ages
by Race: 2002-2006 (includes corresponding Graph/Chart) III-5
Select Players in the Region III-5
New Drug Approvals III-11
Strategic Corporate Developments III-13
B.Market Analytics III-18
Table 12: US Recent Past, Current & Future Analysis for
Lymphoma Drugs Market with Annual Sales in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-18
2. EUROPE III-19
A.Market Analysis III-19
Europe - The Largest Market for Lymphoma Therapeutics Worldwide III-19
Incidence of NHL Continues to Climb III-19
Table 13: Annual Incidence of Non-Hodgkin’s Lymphomas in
Europe: 2003-2010 (includes corresponding Graph/Chart) III-19
Table 14: Incidence Rates of Key Types of Non-Hodgkin’s
Lymphomas in Europe:2006 (includes corresponding
Graph/Chart) III-20
Immunotherapeutic Drugs Dominate the Market III-20
New Drugs to Transform Non-Hodgkins Lymphoma Market III-21
Restraining Forces Loom Large Over New Drugs III-21
An Overview of Lymphomas in United Kingdom III-21
Table 15: Hodgkin’s Lymphoma Incidence in UK (2006) III-22
Table 16: Hodgkin’s Lymphoma Incidence in UK by Sex (2006):
Percentage Breakdown by Age Group (includes corresponding
Graph/Chart) III-22
Select Players in the Region III-22
New Drug Approvals III-24
Strategic Corporate Developments III-25
B.Market Analytics III-26
Table 17: European Recent Past, Current & Future Analysis
for Lymphoma Drugs Market with Annual Sales in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-26
3. REST OF WORLD III-27
A.Market Analysis III-27
Rest of World Lymphoma Therapeutics Market to Witness Rapid
Growth III-27
Select Players in the Region III-27
Strategic Corporate Developments III-28
B.Market Analytics III-29
Table 18: Rest of World Recent Past, Current & Future
Analysis for Lymphoma Drugs Market with Annual Sales in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-29
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 93 (including Divisions/Subsidiaries - 104)
Canada 6
Japan 7
Europe 17
France 4
Germany 5
The United Kingdom 3
Spain 1
Rest of Europe 4
Asia-Pacific (Excluding Japan) 3
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Types of Lymphomas I-3
Hodgkin’s lymphoma I-3
Non-Hodgkin’s lymphoma I-3
II. Executive Summary
1. GLOBAL OUTLOOK II-1
Global Lymphoma Therapeutics Market to Surge II-1
Europe Leads the Global Lymphoma Therapeutics Market II-1
Lymphoma Incidence and Mortality Rates On the Rise II-1
Incidence of Hodgkins Lymphoma - High in West Asia II-2
Table 1: Age-Standardized Incidence Rates for Hodgkin’s
Lymphoma in Select Countries Worldwide (2002) (includes
corresponding Graph/Chart) II-2
Table 2: Age-Standardized Mortality Rates for Hodgkin’s
Lymphoma in Select Countries Worldwide (2002) (includes
corresponding Graph/Chart) II-3
Rituxan’s Dominance - A Major Hurdle to Other Emerging Drugs II-3
Huge Unmet Needs to Drive Product Innovation II-4
Radioimmunotherapy Drug Penetration Continues to Remain Lower II-4
Table 3: Monthly Cost of Select Non-Hodgkin’s Lymphoma
Treatments (2009) II-4
Sales of Zevalin to Gain Momentum II-5
Combination Drugs - A Potential Winning Option for Manufacturers II-5
Existing Drugs for Lymphoma II-6
Select Approved Drugs In Lymphoma Treatment II-6
Rituxan - the Undisputed Leader in NHL Drugs II-6
Key Indications for Rituxan in the US II-7
Zevalin (Biogen Idec) II-7
Overview II-7
Administration II-8
Efficacy II-8
Bexxar (GlaxoSmithKline) II-9
Ribomustin®/Treanda® II-9
Pipeline Drugs for Lymphoma II-9
Select Pipeline Drugs In Lymphoma Treatment II-9
Select Vaccines In Pipeline for Lymphoma Treatment II-11
Pixantrone (Cell Therapeutics) II-11
Affinitor (Novartis) II-11
SGN-35 (Seattle Genetics) II-11
SAR3419 (ImmunoGen, Inc.) II-12
Overview of Treatment Options for NHL II-12
Chemotherapy II-12
Radiotherapy II-13
Antibody Therapy II-13
Stem Cell Transplants II-13
2. PRODUCT OVERVIEW II-14
Lymphomas II-14
Types of Lymphomas II-14
Hodgkin’s lymphoma II-14
Non-Hodgkin’s lymphoma II-14
Classification - Based on Type of Cells Involved II-14
Hodgkin’s Lymphomas II-15
Natural Killer (NK) and Mature T cell Neoplasms II-15
Mature B cell Neoplasms II-15
Classification - Based on Disease Progression II-16
Indolent Lymphomas II-16
Aggressive Lymphomas II-16
Background II-17
Signs and Symptoms II-17
Etiology and Risk Factors II-17
Immunological functions II-18
Infections II-18
Lifestyle Factors II-18
Diagnosis of Lymphoma II-18
Prognosis II-18
Treatment of Lymphoma II-19
3. DRUG APPROVALS II-20
Gloucester Obtains FDA Clearance for Istodax® in Treating CTCL II-20
Allos Obtains FDA Approval for FOLOTYN™ II-20
Spectrum Receives FDA Approval for Zevalin® Expanded Label II-20
Genzyme Receives European Commission Approval for Mozobil® II-21
Cephalon Obtains FDA Approval for TREANDA for Treating
Indolent NHL II-21
GSK Receives European Approval for Atriance® II-22
4. RECENT INDUSTRY ACTIVITY II-23
Celgene to Acquire Gloucester Pharmaceuticals II-23
Scientists at Cornell Discover New Molecular Mechanism for
Treating NHL II-23
CTI Seeks Orphan Drug Designation for Pixantrone in Europe II-24
FDAs ODAC Recommends Romidepsin’s Approval II-24
Seattle Genetics Completes Enrollment for Brentuximab Vedotin II-24
InNexus Biotechnology to Initiate Business Development for DXL625 II-25
Allos Therapeutics Introduces focusonptcl.com II-25
InNexus Inks Letter of Intent with Genhelix II-25
Pfizer Acquires Wyeth II-25
LLS and FORMA Join Hands to Accelerate Development of New
Therapies II-26
Biovest and idis Ink Partnership Deal for Distribution of
BiovaxID® II-26
SymBio Pharmaceuticals Signs a License Agreement with Eisai II-27
Seattle Genetics Receives Fast Track Designation from FDA for
SGN-35 II-27
Spectrum Acquires ZEVALIN® from RIT Oncology II-27
EpiCept Announces Crinobulin as Generic Name for EPC2407 II-27
CTI Enters Into a Joint Venture with Spectrum Pharmaceuticals II-28
Allos Receives Orphan Drug Designation for Pralatrexate from FDA II-28
Takeda Acquires Millennium Pharmaceuticals II-28
5. FOCUS ON SELECT GLOBAL PLAYERS II-29
Allos Therapeutics, Inc. (US) II-29
Astellas Pharma US, Inc. (US) II-29
Biogen Idec (US) II-29
Biolex Therapeutics, Inc. (US) II-30
Biovest International, Inc. (US) II-30
Cell Therapeutics, Inc. (US) II-31
Cephalon, Inc. (US) II-31
Chugai Pharmaceutical Co., Ltd. (Japan) II-31
Cyclacel Pharmaceuticals, Inc. (US) II-32
Eisai, Ltd. (Japan) II-32
EpiCept Corp. (US) II-33
F. Hoffmann-la Roche Ltd. (Switzerland) II-33
Genentech, Inc. (US) II-33
Genmab (Denmark) II-34
Genitope Corp. (US) II-34
Genzyme Corporation (US) II-35
GlaxoSmithKline, Plc. (UK) II-35
Hana Biosciences, Inc. (US) II-35
ImmunoGen, Inc. (US) II-36
InNexus Biotechnology, Inc. (Canada) II-36
Millennium Pharmaceuticals, Inc. (US) II-36
6. GLOBAL MARKET PERSPECTIVE II-38
Table 4: World Recent Past, Current & Future Analysis for
Lymphoma Drugs Market by Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-38
Table 5: World 10-year Perspective for Lymphoma Drugs Market
by Geographic Region - Percentage Breakdown of Value Sales for
US, Europe and Rest of World Markets for Years 2006, 2009 &
2015 (includes corresponding Graph/Chart) II-39
III. MARKET
1. UNITED STATES III-1
A.Market Analysis III-1
Rising Incidence of Lymphomas to Fuel Market Growth III-1
Mortality Rate Slips III-1
Lymphomas - The Third Leading Cause of Cancer in Children III-1
Table 6: Percentage Breakdown of Cancer Incidence in US
Children by Type (2006) (includes corresponding
Graph/Chart) III-2
White Children - Most Susceptible to Lymphomas III-2
Table 7: Incidence of Lymphoma in US Children in 2006
(includes corresponding Graph/Chart) III-2
Lymphoma Fact Sheet III-3
Incidence Rate Rises in Afro-Americans III-3
Table 8: US Lymphoma Incidence Rates in Men of All Ages by
Race: 2002-2006 (includes corresponding Graph/Chart) III-3
Table 9: US Lymphoma Incidence Rates in Women of All Ages
by Race: 2002-2006 (includes corresponding Graph/Chart) III-4
Table 10: US Lymphoma Mortality Rates in Men of All Ages by
Race: 2002-2006 (includes corresponding Graph/Chart) III-4
Table 11: US Lymphoma Mortality Rates in Women of All Ages
by Race: 2002-2006 (includes corresponding Graph/Chart) III-5
Select Players in the Region III-5
New Drug Approvals III-11
Strategic Corporate Developments III-13
B.Market Analytics III-18
Table 12: US Recent Past, Current & Future Analysis for
Lymphoma Drugs Market with Annual Sales in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-18
2. EUROPE III-19
A.Market Analysis III-19
Europe - The Largest Market for Lymphoma Therapeutics Worldwide III-19
Incidence of NHL Continues to Climb III-19
Table 13: Annual Incidence of Non-Hodgkin’s Lymphomas in
Europe: 2003-2010 (includes corresponding Graph/Chart) III-19
Table 14: Incidence Rates of Key Types of Non-Hodgkin’s
Lymphomas in Europe:2006 (includes corresponding
Graph/Chart) III-20
Immunotherapeutic Drugs Dominate the Market III-20
New Drugs to Transform Non-Hodgkins Lymphoma Market III-21
Restraining Forces Loom Large Over New Drugs III-21
An Overview of Lymphomas in United Kingdom III-21
Table 15: Hodgkin’s Lymphoma Incidence in UK (2006) III-22
Table 16: Hodgkin’s Lymphoma Incidence in UK by Sex (2006):
Percentage Breakdown by Age Group (includes corresponding
Graph/Chart) III-22
Select Players in the Region III-22
New Drug Approvals III-24
Strategic Corporate Developments III-25
B.Market Analytics III-26
Table 17: European Recent Past, Current & Future Analysis
for Lymphoma Drugs Market with Annual Sales in US$ Million
for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-26
3. REST OF WORLD III-27
A.Market Analysis III-27
Rest of World Lymphoma Therapeutics Market to Witness Rapid
Growth III-27
Select Players in the Region III-27
Strategic Corporate Developments III-28
B.Market Analytics III-29
Table 18: Rest of World Recent Past, Current & Future
Analysis for Lymphoma Drugs Market with Annual Sales in US$
Million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-29
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 93 (including Divisions/Subsidiaries - 104)
- --------
- --------
Canada 6
Japan 7
Europe 17
France 4
Germany 5
The United Kingdom 3
Spain 1
Rest of Europe 4
Asia-Pacific (Excluding Japan) 3
Note: Product cover images may vary from those shown
3 of 3
LOADING...
4 of 3
- Allos Therapeutics, Inc. (US)
- Astellas Pharma US, Inc. (US)
- Biogen Idec (US)
- Biolex Therapeutics, Inc. (US)
- Biovest International, Inc. (US)
- Cell Therapeutics, Inc. (US)
- Cephalon, Inc. (US)
- Chugai Pharmaceutical Co., Ltd. (Japan)
- Cyclacel Pharmaceuticals, Inc. (US)
- Eisai, Ltd. (Japan)
- EpiCept Corp. (US)
- F. Hoffmann-la Roche Ltd. (Switzerland)
- Genentech, Inc. (US)
- Genmab (Denmark)
- Genitope Corp. (US)
- Genzyme Corporation (US)
- GlaxoSmithKline, Plc. (UK)
- Hana Biosciences, Inc. (US)
- ImmunoGen, Inc. (US)
- InNexus Biotechnology, Inc. (Canada)
- Millennium Pharmaceuticals, Inc. (US)
Note: Product cover images may vary from those shown
![[MLT] B-Cell Non-Hodgkin Lymphoma - Pipeline Insights, 2017 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/6863/6863067_60px_jpg/bcell_nonhodgkin_lymphoma_pipeline_insights.jpg)
![[MLT] NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/7700/7700669_60px_jpg/nhl_mantle_cell_lymphoma_disease_coverage_forecast_and_market_analysis_to_2034.jpg)
![[MLT] umbralisib - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/8117/8117817_60px_jpg/umbralisib.jpg)
![[MLT] Ublituximab - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/8117/8117716_60px_jpg/ublituximab.jpg)
![[MLT] NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/8118/8118240_60px_jpg/nhl_follicular_lymphoma_forecast_and_market_analysis_fl_to_2026.jpg)